Early in the HIV epidemic, lipodystrophy, characterized by subcutaneous fat loss
(lipoatrophy), with or without central fat accumulation (lipohypertrophy), was recognized as a …

Although INSTI-based regimens are highly efficacious for viral suppression, they appear to
cause more weight gain and treatment emergent obesity than non-INSTI-based regimens …

Background Initiation of antiretroviral therapy (ART) often leads to weight gain. While some
of this weight gain may be an appropriate return-to-health effect, excessive increases in …

Background Recent studies have reported weight gain in virologically suppressed persons
living with human immunodeficiency virus (PLWH) switched from older antiretroviral therapy …

Introduction Weight gain following antiretroviral therapy (ART) initiation is common,
potentially predisposing some persons with HIV (PWH) to cardio‐metabolic disease. We …

Background: With the introduction of integrase strand transfer inhibitor (INSTI)-based
antiretroviral therapy, persons living with HIV have a potent new treatment option. Recently …

In most lifestyle, pharmacological and surgical interventions, weight loss occurs over an
approximately 6-to 9-month period and is followed by a weight plateau and then weight …

Abstract Purpose of Review The proportion of overweight and obese persons with HIV
(PWH) has increased since the introduction of antiretroviral therapy (ART). We aim to …

Background Obesity rates are increasing among HIV-infected individuals, but risk factors for
obesity development on ART remain unclear. Objectives In a cohort of HIV-infected adults in …

Since the introduction of combined antiretroviral therapy (cART) and more effective
treatments for AIDS, there has been a dramatic shift from the weight loss and wasting that …